These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 31637586)

  • 1. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
    Junior NCF; Dos-Santos-Pereira M; Guimarães FS; Del Bel E
    Neurotox Res; 2020 Jan; 37(1):12-29. PubMed ID: 31637586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological bases for a possible effect of cannabidiol in Parkinson's disease.
    Ferreira-Junior NC; Campos AC; Guimarães FS; Del-Bel E; Zimmermann PMDR; Brum Junior L; Hallak JE; Crippa JA; Zuardi AW
    Braz J Psychiatry; 2020 Apr; 42(2):218-224. PubMed ID: 31314869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson's Disease.
    Patricio F; Morales-Andrade AA; Patricio-Martínez A; Limón ID
    Front Pharmacol; 2020; 11():595635. PubMed ID: 33384602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?
    Crippa JAS; Hallak JEC; Zuardi AW; Guimarães FS; Tumas V; Dos Santos RG
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):121-133. PubMed ID: 30706171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders.
    de Fátima Dos Santos Sampaio M; de Paiva YB; Sampaio TB; Pereira MG; Coimbra NC
    Basic Clin Pharmacol Toxicol; 2024 May; 134(5):574-601. PubMed ID: 38477419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications.
    Tambe SM; Mali S; Amin PD; Oliveira M
    J Integr Med; 2023 May; 21(3):236-244. PubMed ID: 36973157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4'-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms.
    Dos Santos Pereira M; Dias de Abreu GH; Vanderlei LCA; Raisman-Vozari R; Guimarães FS; Lu HC; Michel PP; Del Bel E
    Neuropharmacology; 2024 Jun; 251():109926. PubMed ID: 38554815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
    Rosenberg EC; Patra PH; Whalley BJ
    Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's Diseases: a Review.
    Cooray R; Gupta V; Suphioglu C
    Mol Neurobiol; 2020 Nov; 57(11):4878-4890. PubMed ID: 32813239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
    Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
    Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing the differential roles of striatal 5-HT
    Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
    Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease.
    Giuliano C; Francavilla M; Ongari G; Petese A; Ghezzi C; Rossini N; Blandini F; Cerri S
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
    González-Aparicio R; Moratalla R
    Neurobiol Dis; 2014 Feb; 62():416-25. PubMed ID: 24140894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease.
    Baul HS; Manikandan C; Sen D
    Brain Res Bull; 2019 Mar; 146():244-252. PubMed ID: 30664919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoids.
    Grotenhermen F
    Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):507-30. PubMed ID: 16266285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease.
    Silvestro S; Schepici G; Bramanti P; Mazzon E
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33171772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
    Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J
    Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.